Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Determination of Multiple Dosing Parameters: Steady-State, Minimum and Maximum Concentrations01:15

Determination of Multiple Dosing Parameters: Steady-State, Minimum and Maximum Concentrations

204
Gentamicin, an aminoglycoside antibiotic, is commonly administered via intermittent intravenous infusion to treat severe infections. An intermittent one-hour infusion of gentamicin, administered at eight-hour intervals, allows for precise control of plasma drug concentrations, minimizing toxicity while ensuring therapeutic efficacy. Pharmacokinetic principles govern the dynamics of plasma concentrations and can be mathematically described using specific equations.The plasma drug concentration...
204
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

228
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
228
Renal Failure: Dose Adjustments01:11

Renal Failure: Dose Adjustments

396
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
396
Continuous Renal Replacement Therapy01:30

Continuous Renal Replacement Therapy

713
Continuous Renal Replacement Therapy, also known as CRRT, is a procedural treatment for acute kidney injury (AKI) that gradually removes uremic toxins and fluids while maintaining acid-base balance and stabilizing electrolytes. It is particularly useful for hemodynamically unstable patients. Unlike intermittent hemodialysis, which is faster, CRRT provides a gentler approach over 24 hours, closely mimicking the function of natural kidneys. However, CRRT is not ideal for patients with...
713
Rheumatic Heart Disease IV: Nursing Management01:20

Rheumatic Heart Disease IV: Nursing Management

243
AssessmentA comprehensive assessment is essential in managing a patient with rheumatic heart disease (RHD). Begin with obtaining a detailed medical history, including recent streptococcal infections, a history of rheumatic fever, or previously diagnosed rheumatic heart disease. Assess the patient for symptoms such as fever, chest pain, widespread joint pain (arthralgia), tachycardia, pericardial friction rub, muffled heart sounds, heart murmurs, peripheral edema, subcutaneous nodules, and...
243
Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant01:25

Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant

181
In patients with renal disease, dosage adjustments are necessary to maintain therapeutic plasma drug concentrations and prevent toxicity or subtherapeutic exposure. Renal impairment alters drug pharmacokinetics, especially in conditions like uremia, where changes such as prolonged elimination half-life and altered apparent volume of distribution can significantly affect drug disposition. These changes require careful modification of the dosing regimen to achieve the desired clinical...
181

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Reply to the Letter to the Editor: "Interpreting Early Reticulocyte Response After Intravenous Iron Therapy in Heart Failure".

Anatolian journal of cardiology·2026
Same author

The Effect of Renal Artery Stent Implantation on Clinical Outcomes in Patients with Early-Stage (Non-Atrophic Kidney) and Clinically Overt Severe Atherosclerotic Renal Artery Stenosis (ARAS-TR).

Journal of clinical medicine·2026
Same author

Early Divergent Cardiac Adaptation After Hematopoietic Stem Cell Transplantation: A Multimodal Echocardiographic and Electrocardiographic Study.

Diagnostics (Basel, Switzerland)·2026
Same author

Early Echocardiographic Changes Following Transcatheter Aortic Valve Implantation: A Comparative Analysis of Different Transcatheter Aortic Valve Systems.

Journal of cardiovascular development and disease·2026
Same author

Efficacy and safety of combination therapy with statin and ezetimibe in patients failing to achieve target LDL levels at cardiology outpatient clinics in Turkey (COM-TR-OLDL): a real-world observational study.

Lipids in health and disease·2026
Same author

The adjusted ferritin inflammation index: a novel metric for predicting mortality in heart failure with reduced and mildly reduced ejection fraction.

ESC heart failure·2026

Related Experiment Video

Updated: Jan 6, 2026

Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload
05:23

Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload

Published on: March 14, 2017

20.2K

Perennial Parameter for Intravenous Iron Therapy in Heart Failure: Reticulocyte Crisis.

Zeynep Kumral1, Hacer Uysal1, Mehmet Birhan Yılmaz1

  • 1Department of Cardiology, Dokuz Eylül University, Faculty of Medicine, İzmir, Türkiye.

Anatolian Journal of Cardiology
|November 17, 2025
PubMed
Summary

Reticulocyte count increase after IV iron therapy is an early, inflammation-independent marker for heart failure (HF) patients. This measure predicts treatment response, shorter hospital stays, and reduced readmissions, outperforming traditional iron deficiency markers.

More Related Videos

Author Spotlight: Developing a Point-of-Care Hemoglobin Estimation Method for Anemia Management
05:35

Author Spotlight: Developing a Point-of-Care Hemoglobin Estimation Method for Anemia Management

Published on: January 19, 2024

1.3K
Dynamic Light Scattering Analysis for the Determination of the Particle Size of Iron-Carbohydrate Complexes
04:40

Dynamic Light Scattering Analysis for the Determination of the Particle Size of Iron-Carbohydrate Complexes

Published on: July 7, 2023

3.1K

Related Experiment Videos

Last Updated: Jan 6, 2026

Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload
05:23

Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload

Published on: March 14, 2017

20.2K
Author Spotlight: Developing a Point-of-Care Hemoglobin Estimation Method for Anemia Management
05:35

Author Spotlight: Developing a Point-of-Care Hemoglobin Estimation Method for Anemia Management

Published on: January 19, 2024

1.3K
Dynamic Light Scattering Analysis for the Determination of the Particle Size of Iron-Carbohydrate Complexes
04:40

Dynamic Light Scattering Analysis for the Determination of the Particle Size of Iron-Carbohydrate Complexes

Published on: July 7, 2023

3.1K

Area of Science:

  • Cardiology
  • Hematology
  • Pharmacology

Background:

  • Managing comorbidities is crucial in heart failure (HF) treatment.
  • Intravenous (IV) iron is recommended for HF patients with left ventricular ejection fraction (LVEF) <50% to address iron deficiency.
  • Traditional markers like ferritin and transferrin saturation (TSAT) are unreliable due to inflammation and delayed response.

Purpose of the Study:

  • To evaluate early response to IV iron therapy in HF patients.
  • To assess reticulocyte counts as an inflammation-independent marker of treatment efficacy.
  • To compare reticulocyte response with traditional iron markers.

Main Methods:

  • Hospitalized HF patients (LVEF <50%) meeting IV iron criteria were enrolled.
  • Reticulocyte counts were measured at admission and 72-120 hours post-treatment.
  • Associations between reticulocyte counts and hemoglobin (Hb) increase, hospital stay, readmissions, and mortality were analyzed.

Main Results:

  • Higher reticulocyte counts at admission and post-treatment correlated with a ≥1 g/dL Hb increase at 1 month.
  • A ≥9% reticulocyte increase predicted significant Hb rise with 90% specificity.
  • Increased reticulocytes were linked to shorter hospital stays and fewer emergency department readmissions.

Conclusions:

  • Reticulocyte increase within 72-120 hours is an early, inflammation-independent marker of IV iron response in HF.
  • This marker outperforms ferritin and TSAT in assessing treatment efficacy.
  • Elevated baseline reticulocytes may predict therapeutic benefit and indicate active bone marrow response.